Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 3/20 | 0.46 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.46 |
| ▸ | CCR6 | P51684 | 7/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
| ▸ | ULK1 | O75385 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | CCR7 | P32248 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | CTSC | P53634 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1334511 | 1.00 | GABBR2 (0.46) | GABBR2GABBR1CCR6GRM5IRAK4 | |
| SCHEMBL1033459 | 0.84 | PTGS1 (0.41) | GABBR2GABBR1GRM5IRAK4ULK1 | |
| SCHEMBL1033458 | 0.84 | PTGS1 (0.41) | GABBR2GABBR1GRM5IRAK4ULK1 | |
| SCHEMBL12127078 | 0.83 | GABBR2 (0.49) | GABBR2GABBR1GRM5IRAK4MCHR1 | |
| SCHEMBL1333239 | 0.83 | GABBR2 (0.49) | GABBR2GABBR1GRM5IRAK4MCHR1 | |
| SCHEMBL1333238 | 0.83 | GABBR2 (0.49) | GABBR2GABBR1GRM5IRAK4MCHR1 | |
| SCHEMBL12125233 | 0.82 | MAPK1 (0.47) | GRM5IRAK4MCHR1 | |
| SCHEMBL12125232 | 0.82 | MAPK1 (0.47) | GRM5IRAK4MCHR1 | |
| SCHEMBL6885645 | 0.81 | GRM5 (0.48) | GRM5IRAK4FLT3 | |
| SCHEMBL1032533 | 0.79 | MAPK6 (0.47) | GRM5IRAK4PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513242-B2 | Pyrimidine compounds and methods of making and using same | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20110281873-A1 | Pyrimidine Compounds and Methods of Making and Using Same | CYSTIC FIBROSIS FOUNDATION | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281873-A1 | Pyrimidine Compounds and Methods of Making and Using Same | CFTR, GPR17, TYMS | GABBR2 1369/4885GABBR1 1484/4885CCR6 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.